QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.014621v1 35/5/721    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Husain, A. Articles by Hein, D. W. Search for Related Content PubMed PubMed Citation Articles by Husain, A. Articles by Hein, D. W.

Identification of N-Acetyltransferase 2 (NAT2) Transcription Start Sites and Quantitation of NAT2-Specific mRNA in Human Tissues

Department of Pharmacology and Toxicology, James Graham Brown Cancer Center and Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, Kentucky

Human N-acetyltransferase 2 (NAT2) genetic polymorphism is associated with drug toxicity and/or carcinogenesis in various tissues. Knowledge of NAT2 gene structure and expression is critical for understanding these associations. Previous findings suggest that human NAT2 expression is highest in liver and gut but expressed at functional levels in other tissues. A sensitive and specific TaqMan reverse transcriptase-polymerase chain reaction (RT-PCR) assay with intron-spanning primers was developed and used, together with a second TaqMan RT-PCR assay based on amplification of a NAT2 open reading frame (ORF) exon segment, to measure NAT2 mRNA in 29 different human tissues. Cap-dependent amplification of mRNA 5' termini and review of public database information were done to more precisely define the NAT2 promoter(s) and to validate the quantitative RT-PCR assay design. The great majority (40/41) of NAT2 liver cDNAs had 5' termini between 8682 and 8752 nucleotides upstream of the NAT2 ORF exon, and 34 of 40 5' termini were at the –8711 and –8716 adenines. All 59 NAT2 cDNAs with 5' termini in this vicinity, including 40 of the liver isolates and 19 cDNAs in public databases from liver and other sources, showed direct splicing to the ORF exon, with no other noncoding exon detected. NAT2 mRNA was highest in liver, small intestine, and colon and was readily detected in most other tissues, albeit at much lower levels. NAT2 expression in diverse human tissues provides further mechanistic support underlying associations between NAT2 genetic polymorphism, drug toxicity, and/or chemical carcinogenesis.

This article has been cited by other articles:

				F. A. Jefferson, G. H. Xiao, and D. W. Hein 4-Aminobiphenyl Downregulation of NAT2 Acetylator Genotype-Dependent N- and O-acetylation of Aromatic and Heterocyclic Amine Carcinogens in Primary Mammary Epithelial Cell Cultures from Rapid and Slow Acetylator Rats Toxicol. Sci., January 1, 2009; 107(1): 293 - 297. [Abstract] [Full Text] [PDF]

				D. F. Barker, J. M. Walraven, E. H. Ristagno, M. A. Doll, J. C. States, and D. W. Hein Quantitative Tissue and Gene-Specific Differences and Developmental Changes in Nat1, Nat2, and Nat3 mRNA Expression in the Rat Drug Metab. Dispos., December 1, 2008; 36(12): 2445 - 2451. [Abstract] [Full Text] [PDF]

				D. W. Hein, J. Bendaly, J. R. Neale, and M. A. Doll Systemic Functional Expression of N-Acetyltransferase Polymorphism in the F344 Nat2 Congenic Rat Drug Metab. Dispos., December 1, 2008; 36(12): 2452 - 2459. [Abstract] [Full Text] [PDF]

				H. Suzuki, J. S. Morris, Y. Li, M. A. Doll, D. W. Hein, J. Liu, L. Jiao, M. M. Hassan, R. S. Day, M. L. Bondy, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer Carcinogenesis, June 1, 2008; 29(6): 1184 - 1191. [Abstract] [Full Text] [PDF]

				N. Ragunathan, J. Dairou, B. Pluvinage, M. Martins, E. Petit, N. Janel, J.-M. Dupret, and F. Rodrigues-Lima Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition Mol. Pharmacol., June 1, 2008; 73(6): 1761 - 1768. [Abstract] [Full Text] [PDF]

				J. M. Walraven, D. F. Barker, M. A. Doll, and D. W. Hein Tissue Expression and Genomic Sequences of Rat N-acetyltransferases rNat1, rNat2, rNat3, and Functional Characterization of a Novel rNat3*2 Genetic Variant Toxicol. Sci., October 1, 2007; 99(2): 413 - 421. [Abstract] [Full Text] [PDF]

				A. Husain, X. Zhang, M. A. Doll, J. C. States, D. F. Barker, and D. W. Hein Functional Analysis of the Human N-Acetyltransferase 1 Major Promoter: Quantitation of Tissue Expression and Identification of Critical Sequence Elements Drug Metab. Dispos., September 1, 2007; 35(9): 1649 - 1656. [Abstract] [Full Text] [PDF]

				S. Gao, Y. Zhao, L. Kong, P. Toselli, I.-N. Chou, P. Stone, and W. Li Cloning and Characterization of the Rat Lysyl Oxidase Gene Promoter: IDENTIFICATION OF CORE PROMOTER ELEMENTS AND FUNCTIONAL NUCLEAR FACTOR I-BINDING SITES J. Biol. Chem., August 31, 2007; 282(35): 25322 - 25337. [Abstract] [Full Text] [PDF]

				J. M. Walraven, J. O. Trent, and D. W. Hein Computational and Experimental Analyses of Mammalian Arylamine N-Acetyltransferase Structure and Function Drug Metab. Dispos., June 1, 2007; 35(6): 1001 - 1007. [Abstract] [Full Text] [PDF]